R1	AND Arg1:T8 Arg2:T9	
*	OR T13 T12
R2	AND Arg1:T11 Arg2:T13	
R3	Has_value Arg1:T15 Arg2:T16	
R4	Subsumes Arg1:T18 Arg2:T19	
R5	AND Arg1:T17 Arg2:T18	
R6	Has_value Arg1:T18 Arg2:T20	
T1	Condition 23 32	active TB
T2	Condition 48 57	allergies
T3	Non-query-able 42 116	Known allergies to any of the study medications by participant self-report
T4	Pregnancy_considerations 118 161	have a positive pregnancy test at screening
T5	Pregnancy_considerations 167 249	are not willing to use a reliable method of barrier contraception during the study
T6	Pregnancy_considerations 255 272	are breastfeeding
T7	Procedure 274 296	hormonal contraception
T8	Condition 298 310	HIV infected
T9	Drug 335 356	anti-retroviral drugs
T10	Non-query-able 358 406	other drugs that interact with 3HP (see Table 1)
T11	Condition 446 455	resistant
T12	Drug 437 445	rifampin
T13	Drug 430 433	INH
T15	Measurement 462 468	Weight
T16	Value 469 476	< 10 kg
T17	Condition 499 511	liver damage
T18	Measurement 526 548	aspartate transaminase
T19	Measurement 550 553	AST
T20	Value 569 607	more than 3x the upper limit of normal
T21	Condition 636 645	Porphyria
T22	Post-eligibility 667 698	Inability to adhere to protocol
T23	Non-query-able 701 819	Patients may be excluded from the study for other reasons, at the investigator's discretion with detailed documentatio
